United States HER2-negative Breast Cancer Market Report 2016

September 2016 | 118 pages | ID: UB52C0DDED9EN
QYResearch

Abstracts

Notes:

Sales, means the sales volume of HER2-negative Breast Cancer

Revenue, means the sales value of HER2-negative Breast Cancer

This report studies sales (consumption) of HER2-negative Breast Cancer in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering

• F. Hoffmann-La Roche
• Novartis
• Pfizer
• AbbVie
• AstraZeneca
• BioMarin
• Bristol-Myers Squibb
• Eisai
• Eli Lilly
• Galena Biopharma
• Incyte
• Merck
• Merck Serono
• Merrimack
• Nektar
• Tesaro

Split by product types, with sales, revenue, price, market share and growth rate of each type, can be divided into

• Type I
• Type II
• Type III

Split by applications, this report focuses on sales, market share and growth rate of HER2-negative Breast Cancer in each application, can be divided into

• Application 1
• Application 2
• Application 3

Contents

United States HER2-negative Breast Cancer Market Report 2016

1 HER2-NEGATIVE BREAST CANCER OVERVIEW

1.1 Product Overview and Scope of HER2-negative Breast Cancer
1.2 Classification of HER2-negative Breast Cancer
  1.2.1 Type I
  1.2.2 Type II
  1.2.3 Type III
1.3 Application of HER2-negative Breast Cancer
  1.3.1 Application
  1.3.2 Application
  1.3.3 Application
1.4 United States Market Size Sales (Value) and Revenue (Volume) of HER2-negative Breast Cancer (2011-2021)
  1.4.1 United States HER2-negative Breast Cancer Sales and Growth Rate (2011-2021)
  1.4.2 United States HER2-negative Breast Cancer Revenue and Growth Rate (2011-2021)

2 UNITED STATES HER2-NEGATIVE BREAST CANCER COMPETITION BY MANUFACTURERS

2.1 United States HER2-negative Breast Cancer Sales and Market Share of Key Manufacturers (2015 and 2016)
2.2 United States HER2-negative Breast Cancer Revenue and Share by Manufactures (2015 and 2016)
2.3 United States HER2-negative Breast Cancer Average Price by Manufactures (2015 and 2016)
2.4 HER2-negative Breast Cancer Market Competitive Situation and Trends
  2.4.1 HER2-negative Breast Cancer Market Concentration Rate
  2.4.2 HER2-negative Breast Cancer Market Share of Top 3 and Top 5 Manufacturers
  2.4.3 Mergers & Acquisitions, Expansion

3 UNITED STATES HER2-NEGATIVE BREAST CANCER SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (2011-2016)

3.1 United States HER2-negative Breast Cancer Sales and Market Share by Type (2011-2016)
3.2 United States HER2-negative Breast Cancer Revenue and Market Share by Type (2011-2016)
3.3 United States HER2-negative Breast Cancer Price by Type (2011-2016)
3.4 United States HER2-negative Breast Cancer Sales Growth Rate by Type (2011-2016)

4 UNITED STATES HER2-NEGATIVE BREAST CANCER SALES (VOLUME) BY APPLICATION (2011-2016)

4.1 United States HER2-negative Breast Cancer Sales and Market Share by Application (2011-2016)
4.2 United States HER2-negative Breast Cancer Sales Growth Rate by Application (2011-2016)
4.3 Market Drivers and Opportunities

5 UNITED STATES HER2-NEGATIVE BREAST CANCER MANUFACTURERS PROFILES/ANALYSIS

5.1 F. Hoffmann-La Roche
  5.1.1 Company Basic Information, Manufacturing Base and Competitors
  5.1.2 HER2-negative Breast Cancer Product Type, Application and Specification
    5.1.2.1 Type I
    5.1.2.2 Type II
  5.1.3 F. Hoffmann-La Roche HER2-negative Breast Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
  5.1.4 Main Business/Business Overview
5.2 Novartis
  5.2.2 HER2-negative Breast Cancer Product Type, Application and Specification
    5.2.2.1 Type I
    5.2.2.2 Type II
  5.2.3 Novartis HER2-negative Breast Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
  5.2.4 Main Business/Business Overview
5.3 Pfizer
  5.3.2 HER2-negative Breast Cancer Product Type, Application and Specification
    5.3.2.1 Type I
    5.3.2.2 Type II
  5.3.3 Pfizer HER2-negative Breast Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
  5.3.4 Main Business/Business Overview
5.4 AbbVie
  5.4.2 HER2-negative Breast Cancer Product Type, Application and Specification
    5.4.2.1 Type I
    5.4.2.2 Type II
  5.4.3 AbbVie HER2-negative Breast Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
  5.4.4 Main Business/Business Overview
5.5 AstraZeneca
  5.5.2 HER2-negative Breast Cancer Product Type, Application and Specification
    5.5.2.1 Type I
    5.5.2.2 Type II
  5.5.3 AstraZeneca HER2-negative Breast Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
  5.5.4 Main Business/Business Overview
5.6 BioMarin
  5.6.2 HER2-negative Breast Cancer Product Type, Application and Specification
    5.6.2.1 Type I
    5.6.2.2 Type II
  5.6.3 BioMarin HER2-negative Breast Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
  5.6.4 Main Business/Business Overview
5.7 Bristol-Myers Squibb
  5.7.2 HER2-negative Breast Cancer Product Type, Application and Specification
    5.7.2.1 Type I
    5.7.2.2 Type II
  5.7.3 Bristol-Myers Squibb HER2-negative Breast Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
  5.7.4 Main Business/Business Overview
5.8 Eisai
  5.8.2 HER2-negative Breast Cancer Product Type, Application and Specification
    5.8.2.1 Type I
    5.8.2.2 Type II
  5.8.3 Eisai HER2-negative Breast Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
  5.8.4 Main Business/Business Overview
5.9 Eli Lilly
  5.9.2 HER2-negative Breast Cancer Product Type, Application and Specification
    5.9.2.1 Type I
    5.9.2.2 Type II
  5.9.3 Eli Lilly HER2-negative Breast Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
  5.9.4 Main Business/Business Overview
5.10 Galena Biopharma
  5.10.2 HER2-negative Breast Cancer Product Type, Application and Specification
    5.10.2.1 Type I
    5.10.2.2 Type II
  5.10.3 Galena Biopharma HER2-negative Breast Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
  5.10.4 Main Business/Business Overview
5.11 Incyte
5.12 Merck
5.13 Merck Serono
5.14 Merrimack
5.15 Nektar
5.16 Tesaro

6 HER2-NEGATIVE BREAST CANCER MANUFACTURING COST ANALYSIS

6.1 HER2-negative Breast Cancer Key Raw Materials Analysis
  6.1.1 Key Raw Materials
  6.1.2 Price Trend of Key Raw Materials
  6.1.3 Key Suppliers of Raw Materials
  6.1.4 Market Concentration Rate of Raw Materials
6.2 Proportion of Manufacturing Cost Structure
  6.2.1 Raw Materials
  6.2.2 Labor Cost
  6.2.3 Manufacturing Expenses
6.3 Manufacturing Process Analysis of HER2-negative Breast Cancer

7 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

7.1 HER2-negative Breast Cancer Industrial Chain Analysis
7.2 Upstream Raw Materials Sourcing
7.3 Raw Materials Sources of HER2-negative Breast Cancer Major Manufacturers in 2015
7.4 Downstream Buyers

8 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

8.1 Marketing Channel
  8.1.1 Direct Marketing
  8.1.2 Indirect Marketing
  8.1.3 Marketing Channel Development Trend
8.2 Market Positioning
  8.2.1 Pricing Strategy
  8.2.2 Brand Strategy
  8.2.3 Target Client
8.3 Distributors/Traders List

9 MARKET EFFECT FACTORS ANALYSIS

9.1 Technology Progress/Risk
  9.1.1 Substitutes Threat
  9.1.2 Technology Progress in Related Industry
9.2 Consumer Needs/Customer Preference Change
9.3 Economic/Political Environmental Change

10 UNITED STATES HER2-NEGATIVE BREAST CANCER MARKET FORECAST (2016-2021)

10.1 United States HER2-negative Breast Cancer Sales, Revenue Forecast (2016-2021)
10.2 United States HER2-negative Breast Cancer Sales Forecast by Type (2016-2021)
10.3 United States HER2-negative Breast Cancer Sales Forecast by Application (2016-2021)
10.4 HER2-negative Breast Cancer Price Forecast (2016-2021)

11 RESEARCH FINDINGS AND CONCLUSION

12 APPENDIX

Author List
Disclosure Section
Research Methodology
Data Source
Disclaimer

List Of Tables

LIST OF TABLES AND FIGURES

Figure Picture of HER2-negative Breast Cancer
Table Classification of HER2-negative Breast Cancer
Figure United States Sales Market Share of HER2-negative Breast Cancer by Type in 2015
Table Application of HER2-negative Breast Cancer
Figure United States Sales Market Share of HER2-negative Breast Cancer by Application in 2015
Figure United States HER2-negative Breast Cancer Sales and Growth Rate (2011-2021)
Figure United States HER2-negative Breast Cancer Revenue and Growth Rate (2011-2021)
Table United States HER2-negative Breast Cancer Sales of Key Manufacturers (2015 and 2016)
Table United States HER2-negative Breast Cancer Sales Share by Manufacturers (2015 and 2016)
Figure 2015 HER2-negative Breast Cancer Sales Share by Manufacturers
Figure 2016 HER2-negative Breast Cancer Sales Share by Manufacturers
Table United States HER2-negative Breast Cancer Revenue by Manufacturers (2015 and 2016)
Table United States HER2-negative Breast Cancer Revenue Share by Manufacturers (2015 and 2016)
Table 2015 United States HER2-negative Breast Cancer Revenue Share by Manufacturers
Table 2016 United States HER2-negative Breast Cancer Revenue Share by Manufacturers
Table United States Market HER2-negative Breast Cancer Average Price of Key Manufacturers (2015 and 2016)
Figure United States Market HER2-negative Breast Cancer Average Price of Key Manufacturers in 2015
Figure HER2-negative Breast Cancer Market Share of Top 3 Manufacturers
Figure HER2-negative Breast Cancer Market Share of Top 5 Manufacturers
Table United States HER2-negative Breast Cancer Sales by Type (2011-2016)
Table United States HER2-negative Breast Cancer Sales Share by Type (2011-2016)
Figure United States HER2-negative Breast Cancer Sales Market Share by Type in 2015
Table United States HER2-negative Breast Cancer Revenue and Market Share by Type (2011-2016)
Table United States HER2-negative Breast Cancer Revenue Share by Type (2011-2016)
Figure Revenue Market Share of HER2-negative Breast Cancer by Type (2011-2016)
Table United States HER2-negative Breast Cancer Price by Type (2011-2016)
Figure United States HER2-negative Breast Cancer Sales Growth Rate by Type (2011-2016)
Table United States HER2-negative Breast Cancer Sales by Application (2011-2016)
Table United States HER2-negative Breast Cancer Sales Market Share by Application (2011-2016)
Figure United States HER2-negative Breast Cancer Sales Market Share by Application in 2015
Table United States HER2-negative Breast Cancer Sales Growth Rate by Application (2011-2016)
Figure United States HER2-negative Breast Cancer Sales Growth Rate by Application (2011-2016)
Table F. Hoffmann-La Roche Basic Information List
Table F. Hoffmann-La Roche HER2-negative Breast Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Figure F. Hoffmann-La Roche HER2-negative Breast Cancer Sales Market Share (2011-2016)
Table Novartis Basic Information List
Table Novartis HER2-negative Breast Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table Novartis HER2-negative Breast Cancer Sales Market Share (2011-2016)
Table Pfizer Basic Information List
Table Pfizer HER2-negative Breast Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table Pfizer HER2-negative Breast Cancer Sales Market Share (2011-2016)
Table AbbVie Basic Information List
Table AbbVie HER2-negative Breast Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table AbbVie HER2-negative Breast Cancer Sales Market Share (2011-2016)
Table AstraZeneca Basic Information List
Table AstraZeneca HER2-negative Breast Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table AstraZeneca HER2-negative Breast Cancer Sales Market Share (2011-2016)
Table BioMarin Basic Information List
Table BioMarin HER2-negative Breast Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table BioMarin HER2-negative Breast Cancer Sales Market Share (2011-2016)
Table Bristol-Myers Squibb Basic Information List
Table Bristol-Myers Squibb HER2-negative Breast Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table Bristol-Myers Squibb HER2-negative Breast Cancer Sales Market Share (2011-2016)
Table Eisai Basic Information List
Table Eisai HER2-negative Breast Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table Eisai HER2-negative Breast Cancer Sales Market Share (2011-2016)
Table Eli Lilly Basic Information List
Table Eli Lilly HER2-negative Breast Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table Eli Lilly HER2-negative Breast Cancer Sales Market Share (2011-2016)
Table Galena Biopharma Basic Information List
Table Galena Biopharma HER2-negative Breast Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table Galena Biopharma HER2-negative Breast Cancer Sales Market Share (2011-2016)
Table Incyte Basic Information List
Table Incyte HER2-negative Breast Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table Incyte HER2-negative Breast Cancer Sales Market Share (2011-2016)
Table Merck Basic Information List
Table Merck HER2-negative Breast Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table Merck HER2-negative Breast Cancer Sales Market Share (2011-2016)
Table Merck Serono Basic Information List
Table Merck Serono HER2-negative Breast Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table Merck Serono HER2-negative Breast Cancer Sales Market Share (2011-2016)
Table Merrimack Basic Information List
Table Merrimack HER2-negative Breast Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table Merrimack HER2-negative Breast Cancer Sales Market Share (2011-2016)
Table Nektar Basic Information List
Table Nektar HER2-negative Breast Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table Nektar HER2-negative Breast Cancer Sales Market Share (2011-2016)
Table Tesaro Basic Information List
Table Tesaro HER2-negative Breast Cancer Sales, Revenue, Price and Gross Margin (2011-2016)
Table Tesaro HER2-negative Breast Cancer Sales Market Share (2011-2016)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of HER2-negative Breast Cancer
Figure Manufacturing Process Analysis of HER2-negative Breast Cancer
Figure HER2-negative Breast Cancer Industrial Chain Analysis
Table Raw Materials Sources of HER2-negative Breast Cancer Major Manufacturers in 2015
Table Major Buyers of HER2-negative Breast Cancer
Table Distributors/Traders List
Figure United States HER2-negative Breast Cancer Production and Growth Rate Forecast (2016-2021)
Figure United States HER2-negative Breast Cancer Revenue and Growth Rate Forecast (2016-2021)
Table United States HER2-negative Breast Cancer Production Forecast by Type (2016-2021)
Table United States HER2-negative Breast Cancer Consumption Forecast by Application (2016-2021)